MX2021014948A - Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. - Google Patents
Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.Info
- Publication number
- MX2021014948A MX2021014948A MX2021014948A MX2021014948A MX2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A
- Authority
- MX
- Mexico
- Prior art keywords
- serotype
- pneumoniae
- treating patients
- methods
- immunogenic composition
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 2
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- 229940031670 conjugate vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857534P | 2019-06-05 | 2019-06-05 | |
| PCT/US2020/035511 WO2020247301A1 (en) | 2019-06-05 | 2020-06-01 | Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014948A true MX2021014948A (es) | 2022-01-24 |
Family
ID=73653320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014948A MX2021014948A (es) | 2019-06-05 | 2020-06-01 | Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220218812A1 (enExample) |
| EP (1) | EP3980050A4 (enExample) |
| JP (1) | JP2022535064A (enExample) |
| KR (1) | KR20220016964A (enExample) |
| CN (1) | CN114025784A (enExample) |
| AU (1) | AU2020289048A1 (enExample) |
| BR (1) | BR112021024491A8 (enExample) |
| CA (1) | CA3142697A1 (enExample) |
| MX (1) | MX2021014948A (enExample) |
| WO (1) | WO2020247301A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110225764A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 制备多糖-蛋白缀合物的方法 |
| CA3050120A1 (en) | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
| KR102734995B1 (ko) | 2017-09-07 | 2024-11-26 | 머크 샤프 앤드 돔 엘엘씨 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| KR102736151B1 (ko) | 2017-09-07 | 2024-11-28 | 머크 샤프 앤드 돔 엘엘씨 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| UA128603C2 (uk) | 2017-12-06 | 2024-08-28 | Мерк Шарп Енд Доум Елелсі | Полівалентна імуногенна композиція проти пневмококового захворювання |
| CN112074294B (zh) | 2018-04-30 | 2025-07-11 | 默沙东有限责任公司 | 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法 |
| CN120661645A (zh) | 2018-04-30 | 2025-09-19 | 默沙东有限责任公司 | 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法 |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311976A1 (en) * | 2009-10-19 | 2011-04-20 | Azienda Ospedaliero-Universitaria Meyer | Method for Streptococcus Pneumoniae diagnosis and serotyping |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| WO2017173415A2 (en) * | 2016-03-31 | 2017-10-05 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| EP3518965A1 (en) * | 2016-09-30 | 2019-08-07 | Biological E Limited | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| US11998599B2 (en) * | 2016-12-30 | 2024-06-04 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
-
2020
- 2020-06-01 MX MX2021014948A patent/MX2021014948A/es unknown
- 2020-06-01 JP JP2021571699A patent/JP2022535064A/ja active Pending
- 2020-06-01 EP EP20819293.0A patent/EP3980050A4/en not_active Withdrawn
- 2020-06-01 BR BR112021024491A patent/BR112021024491A8/pt unknown
- 2020-06-01 AU AU2020289048A patent/AU2020289048A1/en not_active Abandoned
- 2020-06-01 WO PCT/US2020/035511 patent/WO2020247301A1/en not_active Ceased
- 2020-06-01 CN CN202080049226.4A patent/CN114025784A/zh active Pending
- 2020-06-01 CA CA3142697A patent/CA3142697A1/en active Pending
- 2020-06-01 KR KR1020227000140A patent/KR20220016964A/ko not_active Withdrawn
- 2020-06-01 US US17/614,876 patent/US20220218812A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021024491A2 (pt) | 2022-02-15 |
| AU2020289048A1 (en) | 2021-12-09 |
| WO2020247301A1 (en) | 2020-12-10 |
| CA3142697A1 (en) | 2020-12-10 |
| EP3980050A1 (en) | 2022-04-13 |
| EP3980050A4 (en) | 2023-08-02 |
| CN114025784A (zh) | 2022-02-08 |
| JP2022535064A (ja) | 2022-08-04 |
| BR112021024491A8 (pt) | 2023-04-11 |
| US20220218812A1 (en) | 2022-07-14 |
| KR20220016964A (ko) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014948A (es) | Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. | |
| PH12020550891A1 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
| PH12021551448A1 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
| CY1123838T1 (el) | Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματος | |
| ZA201901170B (en) | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates | |
| MX2020002555A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
| MX2020002556A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
| NZ755770A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| MY182282A (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| EP3863667A4 (en) | POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE VACCINE | |
| TN2019000064A1 (en) | Composition comprising multivalent capsular polysaccharide-transport protein and use thereof | |
| MX2021005500A (es) | Composiciones inmunogenicas de glicoconjugados multivalentes. | |
| WO2019157188A3 (en) | Compositions and methods for cross-protection against pneumococcal disease | |
| WO2009129498A3 (en) | Substance p and analogs thereof as a cancer immunogenic composition adjuvant | |
| MX2013002841A (es) | Composiciones inmunogenas. |